Compare LNN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | IVA |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | N/A |
| Metric | LNN | IVA |
|---|---|---|
| Price | $109.07 | $5.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $113.00 | $16.20 |
| AVG Volume (30 Days) | 153.4K | ★ 230.6K |
| Earning Date | 04-02-2026 | 03-30-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $676,368,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | $751.20 |
| P/E Ratio | $40.49 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $97.27 | $2.94 |
| 52 Week High | $149.56 | $7.98 |
| Indicator | LNN | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 43.70 |
| Support Level | $106.63 | $4.98 |
| Resistance Level | $115.75 | $6.42 |
| Average True Range (ATR) | 3.43 | 0.26 |
| MACD | 0.28 | -0.02 |
| Stochastic Oscillator | 45.63 | 25.00 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.